Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).

Autor: Julia González-Rincón, José A Garcia-Vela, Sagrario Gómez, Belén Fernández-Cuevas, Sara Nova-Gurumeta, Nuria Pérez-Sanz, Miguel Alcoceba, Marcos González, Eduardo Anguita, Javier López-Jiménez, Eva González-Barca, Lucrecia Yáñez, Ernesto Pérez-Persona, Javier de la Serna, Miguel Fernández-Zarzoso, Guillermo Deben, Francisco J Peñalver, María C Fernández, Jaime Pérez de Oteyza, M Ángeles Andreu, M Ángeles Ruíz-Guinaldo, Raquel Paz-Arias, M Dolores García-Malo, Valle Recasens, Rosa Collado, Raúl Córdoba, Belén Navarro-Matilla, Margarita Sánchez-Beato, José A García-Marco

Publikováno v: PLoS ONE, Vol 16, Iss 9, p e0257353 (2021)

Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in

Externí odkaz: https://doaj.org/article/792f13e07f4d443d9b3335081a4b1ee4

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

Autor: Marcos González, Eduardo Anguita, Ernesto Pérez-Persona, Belén Navarro-Matilla, Sara Nova-Gurumeta, Lucrecia Yáñez, Valle Recasens, Eva González-Barca, Rosa Collado, Javier López-Jiménez, Javier de la Serna, Sagrario Gómez, Raul Cordoba, Belen Fernandez-Cuevas, M.Angeles Andreu, Margarita Sánchez-Beato, María del Carmen Marquetti Fernández, M. Dolores García-Malo, Francisco Javier Peñalver, Nuria Pérez-Sanz, Guillermo Deben, Miguel Alcoceba, M. Ángeles Ruíz-Guinaldo, Raquel Paz-Arias, Miguel Fernández-Zarzoso, José A. García-Marco, Jose A. Garcia-Vela, Jaime Pérez de Oteyza, Julia González-Rincón

Publikováno v: PLoS One
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
PLoS ONE, Vol 16, Iss 9, p e0257353 (2021)
PLoS ONE
r-FISABIO. Repositorio Institucional de Producción Científica
Dipòsit Digital de la UB
Universidad de Barcelona

Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b7c900b119d468b1a8ae042f0c38ee7
https://fundanet.fihgu.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1958

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

Autor: José A. García-Marco, Javier López Jiménez, Valle Recasens, Miguel Fernández Zarzoso, Eva González-Barca, Nieves Somolinos De Marcos, M. Jose Ramírez, Francisco Javier Peñalver Parraga, Lucrecia Yañez, Javier De La Serna Torroba, Maria Dolores Garcia Malo, Guillermo Deben Ariznavarreta, Ernesto Perez Persona, M. Angeles Ruiz Guinaldo, Raquel De Paz Arias, Elena Bañas Llanos, Isidro Jarque, M. del Carmen Fernandez Valle, Ana Carral Tatay, Jaime Perez De Oteyza, Eva Maria Donato Martin, Inmaculada Perez Fernández, Rafael Martinez Martinez, M. Angeles Andreu Costa, Diana Champ, Julio García Suarez, Marcos González Díaz, Secundino Ferrer, Félix Carbonell, José A. García-Vela

Publikováno v: Haematologica, Vol 104, Iss 11 (2019)

It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. In this s

Externí odkaz: https://doaj.org/article/fb9a08ed52534cc49c34466240ad698c

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.